Research Article
No access
Published Online: 3 January 2006

Elimination of Innate Immune Responses and Liver Inflammation by PEGylation of Adenoviral Vectors and Methylprednisolone

Publication: Human Gene Therapy
Volume 16, Issue Number 12

Abstract

Improvement of the therapeutic index of adenoviral gene transfer requires the development of strategies to abrogate adenoviral capsid-induced inflammation and cytokine production. The effect of monomethoxypolyethylene glycol (MPEG) conjugation to adenoviral vectors and of methylprednisolone (MP) on innate immunity, liver inflammation, and thrombocyte counts was evaluated after transfer of 1011 particles of E1/E3/E4- deleted adenoviral vector expressing human apolipoprotein A-I (apoA-I). Gene transfer with unPEGylated vectors induced peak interleukin-6 (IL-6) plasma levels that were 66-fold above baseline levels in C57BL/6 mice. PEGylation combined with 4 mg of MP 6 hr before and at the time of gene transfer suppressed IL-6 plasma levels to baseline values at all time points. This combination resulted in 24-, 28-, 5.9-, 42-, 26-, and 2.5- fold reduced mRNA expression in the liver of monocyte chemoattractant protein-1, macrophage inflammatory protein-2, interferon-inducible protein-10, macrophage inflammatory protein-1β, lipopolysaccharide-induced CXC chemokine, and keratinocyte-derived chemokine, respectively; abrogated neutrophil infiltration in the liver; and reduced alanine aminotransferase levels. PEGylation reduced vector uptake in the spleen and in nonparenchymal liver cells. PEGylation also inhibited the development of thrombocytopenia. In conclusion, PEGylation of adenoviral vectors combined with MP administration improves the therapeutic index of adenoviral gene transfer.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Human Gene Therapy
Human Gene Therapy
Volume 16Issue Number 12December 2005
Pages: 1439 - 1451
PubMed: 16390275

History

Published online: 3 January 2006
Published in print: December 2005

Permissions

Request permissions for this article.

Authors

Affiliations

Dr. Bart De Geest
Center for Molecular and Vascular Biology, University of Leuven, 3000 Leuven, Belgium.
Jan Snoeys
Center for Molecular and Vascular Biology, University of Leuven, 3000 Leuven, Belgium.
Sophie Van Linthout
Center for Molecular and Vascular Biology, University of Leuven, 3000 Leuven, Belgium.
Joke Lievens
Center for Molecular and Vascular Biology, University of Leuven, 3000 Leuven, Belgium.
Désiré Collen
Center for Molecular and Vascular Biology, University of Leuven, 3000 Leuven, Belgium.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top